2,4-diamino-5-(4-isopropylbenzyl)pyrimidine | 110224-68-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 2,4-diamino-5-(4-isopropylbenzyl)pyrimidine
• 英文别名: 5-[(4-Propan-2-ylphenyl)methyl]pyrimidine-2,4-diamine
• CAS: 110224-68-5
• 化学式: C₁₄H₁₈N₄
• 分子量: 242.324
• InChiKey: NARCKBGBYYTPIH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  77.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  4-异丙基苯甲醛 在 sodium methylate 、 二甲基亚砜 作用下， 以 乙醇 、 二甲基亚砜 为溶剂， 生成 2,4-diamino-5-(4-isopropylbenzyl)pyrimidine
  参考文献：
  名称：

  Immobilization of Malarial (Plasmodium falciparum) Dihydrofolate Reductase for the Selection of Tight-Binding Inhibitors from Combinatorial Library

  摘要：

  已经描述了一种基于优先结合固定在Sepharose柱上的酶的选择突变型恶性疟原虫二氢叶酸还原酶（PfDHFRs）的紧密结合抑制剂的简单程序。为了通过S-S键固定到硫丙基-Sepharose凝胶上，制备了在C末端具有半胱氨酸残基的PfDHFRs。估计固定化的DHFRs量为4-5毫克/克干燥凝胶，并且与自由酶的活性相当。制备的固定化酶已被用于从组合库中选择紧密结合抑制剂，基于每个配体与酶的亲和力。然后通过高效液相色谱-质谱法识别和定量分析自由配体，从而实现库中具有高结合亲和力的成分。结果可以通过定量分析通过盐酸胍处理从酶中释放的结合配体来确认。

  DOI：

  10.1021/ac070215s

文献信息

• [EN] NOVEL PIPERAZINYLALKYLTHIOPYRIMIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND A PROCESS FOR THE PREPARATION OF THE NOVEL COMPOUNDS<br/>[FR] NOUVEAUX DERIVES DE PIPERAZINYLALKYLTHIOPYRIMIDINE, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT ET LEUR PROCEDE DE PREPARATION
  申请人：EGIS GYÓGYSZERGYÁR RT.

  公开号：WO1997016429A1

  公开（公告）日：1997-05-09

  (EN) The invention refers to novel piperazinylalkylthiopyrimidine derivatives of formula (I) being suitable for the treatment of diseases due to pathological alterations of the central nervous system, pharmaceutical compositions containing the above derivatives, and a process for the preparation of the novel compounds.(FR) L'invention se rapporte à de nouveaux dérivés de piperazinyl-alkylthiopyrimidine de la formule (I) appropriés au traitement de maladies dues à des modifications pathologiques du système nerveux central. L'invention se rapporte également à des compositions pharmaceutiques contenant les dérivés mentionnés ci-dessus ainsi qu'à un procédé de préparation de ces nouveaux composés.

  该发明涉及一种新型的piperazinylalkylthiopyrimidine衍生物，其化学式为（I），适用于治疗由中枢神经系统病理变化引起的疾病，包括含有上述衍生物的制药组合物，以及制备新化合物的方法。
• 2,4-Diamino-5-benzylpyrimidines as antibacterial agents. 8. The 3,4,5-triethyl isostere of trimethoprim. A study of specificity
  作者：Barbara Roth、Edward Aig

  DOI：10.1021/jm00394a012

  日期：1987.11

  3,4,5-Triethylacetophenone was synthesized in 60% yield by a Friedel-Crafts reaction from 4-ethylacetophenone and converted to 2,4-diamino-5-(3,4,5-triethylbenzyl)pyrimidine (2), a trimethoprim (1) isostere, by standard techniques. This compound is more lipophilic than 1 by three log units (log P, octanol/water). Compound 2 was approximately equipotent with 1 in inhibiting Escherichia coli dihydrofolate reductase (DHFR), 2-fold more potent against P. berghei and N. gonorrhoeae DHFR, and 10 and 25 times better an inhibitor of rat and chicken liver DHFR, respectively. Although the 3,4-dimethoxy analogue 19 was 10-fold less inhibitory to E. coli DHFR than 1, it was 3-4 times more potent on the vertebrate isozymes, whereas the diethyl congener 10 followed 19 in its E. coli DHFR binding but was less active on rat and chicken DHFR. Therefore, a significant portion of the selectivity of 1 for bacterial, as opposed to vertebrate, DHFR, involves the methoxy functions. An analysis of the X-ray data on 1 and 2 complexed with chicken DHFR, coupled with kinetic data, led to the conclusion that the difference in binding energies of the methoxy and ethyl compounds probably involve desolvation factors, as well as direct energies of interaction with protein atoms. Thus, one cannot invoke lipophilicity or shape alone in explaining the relationship in properties of 1 and 2.
• ROTH, BARBARA;AIG, EDWARD, J. MED. CHEM., 30,(1987) N 11, 1998-2004
  作者：ROTH, BARBARA、AIG, EDWARD

  DOI：——

  日期：——
• NOVEL PIPERAZINYLALKYLTHIOPYRIMIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND A PROCESS FOR THE PREPARATION OF THE NOVEL COMPOUNDS
  申请人：EGIS GYOGYSZERGYAR RT.

  公开号：EP0901473A1

  公开（公告）日：1999-03-17
• Immobilization of Malarial (<i>Plasmodium falciparum</i>) Dihydrofolate Reductase for the Selection of Tight-Binding Inhibitors from Combinatorial Library
  作者：Chawanee Thongpanchang、Supannee Taweechai、Sumalee Kamchonwongpaisan、Yongyuth Yuthavong、Yodhathai Thebtaranonth

  DOI：10.1021/ac070215s

  日期：2007.7.1

  A simple procedure for selection of tight-binding inhibitors of mutant dihydrofolate reductases from Plasmodium falciparum (PfDHFRs) based on preferential binding to the enzyme immobilized on a Sepharose column has been described. PfDHFRs with a cysteine residue at the C-terminal have been prepared in order to immobilize to a thiopropyl-Sepharose gel via S−S linkage. The amount of immobilized DHFRs was estimated to be 4−5 mg/g of dried gel, and the activities of bound DHFRs were comparable to that of free enzymes. The prepared immobilized enzyme has been used for the selection of tight-binding inhibitors from combinatorial libraries, based on the affinities of each ligand with the enzyme. Free ligands were then identified and analyzed quantitatively by high-performance liquid chromatography−mass spectrometry, and the components with high binding affinity of the library could thus be realized. Results could be confirmed by quantitative analysis of the bound ligands released from the enzyme by guanidine hydrochloride treatment.

  已经描述了一种基于优先结合固定在Sepharose柱上的酶的选择突变型恶性疟原虫二氢叶酸还原酶（PfDHFRs）的紧密结合抑制剂的简单程序。为了通过S-S键固定到硫丙基-Sepharose凝胶上，制备了在C末端具有半胱氨酸残基的PfDHFRs。估计固定化的DHFRs量为4-5毫克/克干燥凝胶，并且与自由酶的活性相当。制备的固定化酶已被用于从组合库中选择紧密结合抑制剂，基于每个配体与酶的亲和力。然后通过高效液相色谱-质谱法识别和定量分析自由配体，从而实现库中具有高结合亲和力的成分。结果可以通过定量分析通过盐酸胍处理从酶中释放的结合配体来确认。